VIVID-1 trial: More than half of mirikizumab users achieve clinical remission in Crohn’s

Topline findings from the phase 3 VIVID-1 trial showed Eli Lilly’s mirikizumab, an interleukin-23p19 antagonist, demonstrated clinical remission and endoscopic response through 52 weeks in adults with moderate to severe Crohn’s disease.
According to a company press release, this was the first double-blind placebo and active controlled trial assessing an IL-23p19 antibody.
“I’m excited by these results, which showed more than half of patients on mirikizumab achieved clinical remission as measured by [Crohn’s Disease Activity Index] at one year,” Lotus

Topline findings from the phase 3 VIVID-1 trial showed Eli Lilly’s mirikizumab, an interleukin-23p19 antagonist, demonstrated clinical remission and endoscopic response through 52 weeks in adults with moderate to severe Crohn’s disease.
According to a company press release, this was the first double-blind placebo and active controlled trial assessing an IL-23p19 antibody.
“I’m excited by these results, which showed more than half of patients on mirikizumab achieved clinical remission as measured by [Crohn’s Disease Activity Index] at one year,” Lotus